OH Pharma
Products › Skin and aesthetics › Glow 70 mg
Glow 70 mg OH PharmaGlow 70 mg OH Pharma – back of vial

Skin and aesthetics · File 21

Glow 70 mg

Certificate of analysis available

✓Sterility and endotoxins tested by Nelson Labs (Salt Lake City)

Blend of three peptides: BPC‑157, TB‑500 and GHK‑Cu.

BPC‑15710 mg
TB‑50010 mg
GHK‑Cu50 mg
FormatLyophilized powder · 3 mL
Purity (HPLC)99.7 %
LotGN2605
LaboratoryBTLabs

Description

Vial combining three peptides: BPC‑157, a synthetic pentadecapeptide derived from a gastric-juice protein; TB‑500, a synthetic fragment of thymosin beta‑4; and GHK‑Cu, a tripeptide‑copper complex naturally present in human plasma. Total content: 70 mg, to be reconstituted with 3 mL of sterile water.

🔬 What the research says
  • No published study has evaluated this three-peptide blend, in animals or in humans.
  • BPC‑157: many animal studies on tendons, ligaments and the digestive tract; according to the FDA, there is virtually no published clinical data in humans.
  • TB‑500: thymosin beta‑4 has been studied in animals and in a few human trials in topical or ocular form; the injectable fragment has no published clinical trials in humans.
  • GHK‑Cu: human studies mainly cover topical use in skin care; injection has not been studied in humans.

Composition

PeptideStudied roleLabelled amountPage
BPC‑157Tissue repair10 mgView page
TB‑500Tissue repair10 mgView page
GHK‑CuSkin and aesthetics50 mgView page
Total70 mg

The amounts measured by the laboratory for this lot are shown in the results below.

⚠️ Warnings and reported side effects
  • Safety profile unknown in humans, both for each peptide and for their combination.
  • Concerns raised by the FDA for BPC‑157: immune reactions, impurities, theoretical effect on blood-vessel formation (angiogenesis). TB‑500 raises the same theoretical concern.
  • Possible injection-site reactions.

Consult a healthcare professional before any use. If an adverse effect occurs, stop use and see a doctor.

Certificate details

Laboratory
BTLabs (West Palm Beach, FL, United States)
Report number
IF-824-QSA-TR006-BTL26632-08
Substance analyzed
BPC-157, GHK-Cu, TB-500 (Glow)
Lot
GN2605
Analysis date
June 1, 2026
Report date
June 5, 2026
Labelled sample content
70 mg
Sample ID
005000040271696

Results

TestMethodSpecificationResult
AppearanceUSP <630>Mauve powderMauve powderPass
Identity and composition (FTIR)USP <197A>Confirms the presence of the peptidesConfirmed, with excipient(s)Pass
Purity (HPLC)USP <621>≥ 98 %99.7 %Pass
Measured content (HPLC)USP <621>90 – 110 % de 70 mg75.9 mg total (108.4%)Pass
GHK‑Cu 54.1 mg · BPC‑157 10.2 mg · TB‑500 11.6 mg
Peptide : excipient ratioUSP <1151>Recommended 1:2 to 1:1075.9 : 71.1 mg (1:0.9)
Total massUSP <41>As measured147.1 mg

According to the laboratory, this analysis covers identity, purity, content and composition. It does not cover particulates, microbial contamination or endotoxins. Sterility and endotoxins are tested separately by Nelson Labs (Salt Lake City, Utah).

How to read this certificate →

Original certificate

Certificate of analysis Glow 70 mg, page 1Certificate of analysis Glow 70 mg, page 2 Download the certificate (PDF)

Sources

  1. AJMC — FDA position on peptides (August 2026)
  2. Published studies on GHK‑Cu (PubMed)
  3. Health Canada — advisory on unauthorized injectable peptides (April 2026)

For educational purposes only. This information summarizes published studies and is neither a recommendation for use nor medical advice.

← Back to products